Literature DB >> 17557501

GABAA receptors: subtypes, regional distribution, and function.

David Nutt1.   

Abstract

Modulatory agents of gamma-aminobutyric acid type A (GABAA) receptors have been widely used for more than 40 years to treat anxiety, epilepsy, and sleep disorders; these drugs are generally safe, well tolerated, and effective. Recently, there has been a substantial growth in understanding of the mechanism of action of these drugs, which act at different sites on GABAA receptors. A variety of GABAA receptor subtypes with distinct functional roles have been characterized and an evolving awareness of GABAA receptor modulation holds promise for the future development of new, more sophisticated drug interventions that can elicit more selective effects by targeting specific subtypes of GABAA receptors. Advances in genetic engineering have led to the development of transgenic mouse models that have further refined our understanding of the pharmacology and physiology for various GABAA receptor subunits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17557501

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  39 in total

1.  GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors.

Authors:  Randa S Eshaq; Letha D Stahl; Randolph Stone; Sheryl S Smith; Lucy C Robinson; Nancy J Leidenheimer
Journal:  Brain Res       Date:  2010-05-16       Impact factor: 3.252

2.  Amygdala-specific reduction of alpha1-GABAA receptors disrupts the anticonvulsant, locomotor, and sedative, but not anxiolytic, effects of benzodiazepines in mice.

Authors:  Scott A Heldt; Kerry J Ressler
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

3.  Lateral preoptic and ventral pallidal roles in locomotion and other movements.

Authors:  Suriya Subramanian; Rhett A Reichard; Hunter S Stevenson; Zachary M Schwartz; Kenneth P Parsley; Daniel S Zahm
Journal:  Brain Struct Funct       Date:  2018-04-26       Impact factor: 3.270

Review 4.  Neurotransmitter changes after traumatic brain injury: an update for new treatment strategies.

Authors:  Jennifer L McGuire; Laura B Ngwenya; Robert E McCullumsmith
Journal:  Mol Psychiatry       Date:  2018-09-13       Impact factor: 15.992

5.  Anti-Tremor Action of Subtype Selective Positive Allosteric Modulators of GABAA Receptors in a Rat Model of Essential Tremors.

Authors:  Dipak V Amrutkar; Tino Dyhring; Thomas A Jacobsen; Janus S Larsen; Karin Sandager-Nielsen
Journal:  Cerebellum       Date:  2020-04       Impact factor: 3.847

Review 6.  Insomnia pharmacotherapy.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

7.  Improvement of pyridoxine-induced peripheral neuropathy by Cichorium intybus hydroalcoholic extract through GABAergic system.

Authors:  Farkhonde Hasannejad; Malek Moein Ansar; Mohammad Rostampour; Edris Mahdavi Fikijivar; Behrooz Khakpour Taleghani
Journal:  J Physiol Sci       Date:  2019-02-02       Impact factor: 2.781

Review 8.  Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2017-11-15       Impact factor: 4.030

9.  GABAA Receptors in the Mongolian Gerbil: a PET Study Using [18F]Flumazenil to Determine Receptor Binding in Young and Old Animals.

Authors:  M Kessler; M Mamach; R Beutelmann; M Lukacevic; S Eilert; P Bascuñana; A Fasel; F M Bengel; J P Bankstahl; T L Ross; G M Klump; G Berding
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

10.  Pharmacological alterations of anxious behaviour in mice depending on both strain and the behavioural situation.

Authors:  Yan Clément; Anne-Marie Le Guisquet; Patrice Venault; Georges Chapouthier; Catherine Belzung
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.